NCT05320159View on ClinicalTrials.gov

Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

CompletedOBSERVATIONAL
Enrollment

17,743

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Psoriasis
Interventions
DRUG

Secukinumab

Included all the patients treated with secukinumab

Trial Locations (1)

07936-1080

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY